Numerous groups are attempting to diversify COVID vaccine research
With communities of color historically underrepresented in clinical trials, numerous groups are working to diversify COVID-19 vaccine research.
Policy
COVID-19 kicks drug pricing down the road
The attention to the upcoming presidential election also dims the likelihood of legislation efforts until 2021.
House committee to investigate how USPS slowdown affects prescriptions by mail
The House Energy and Commerce subcommittee on health began an investigation this week.
Telehealth executive order aims to extend temporary changes
President Trump’s executive order calls for regulation to make some of the changes permanent.
FDA cracks down on online retailers selling scam COVID-19 treatments
The Food and Drug Administration has issued warning letters in recent weeks to websites selling scam COVID-19 treatments.
Why the dance between manufacturers and PBMs continues
States have targeted co-pay accumulators, claiming they run up costs for patients who need expensive specialty drugs. Here’s why their legislation hasn’t yet had the intended impact.
Dive into the FDA ban on flavored e-cigarettes
Beginning Feb. 1, the e-cigarette industry will look much different.
Questions linger after Hahn takes over as FDA commissioner
Some Senators who questioned Hahn during his confirmation hearing expressed concern about his lack of regulatory and public policy experience.
Infographic: What could you buy with the $20.5 trillion Elizabeth Warren’s health plan calls for in new federal spending?
That number got many of us at MM&M thinking: What else can be bought with $20,500,000,000,000?
It’s back! Bill requiring list prices in DTC ads resurfaces
Sens. Chuck Grassley and Dick Durbin hoped to pass the bill through unanimous consent last week, ahead of impeachment proceedings and a budget battle.
